Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) EPS (Weighted Average and Diluted) (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with -$0.09 as the latest value for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 139.13% to -$0.09 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.56 through Jan 2026, down 74.43% year-over-year, with the annual reading at $0.58 for FY2026, 73.52% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.09 at Usana Health Sciences, up from -$0.36 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.73 in Q1 2022, with the low at -$0.36 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.67, with a median of $0.66 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 31.82% in 2023, then crashed 164.29% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.66 in 2022, then surged by 31.82% to $0.87 in 2023, then tumbled by 73.56% to $0.23 in 2024, then plummeted by 256.52% to -$0.36 in 2025, then soared by 75.0% to -$0.09 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.09, -$0.36, and $0.52 for Q1 2026, Q3 2025, and Q2 2025 respectively.